{"created":"2023-05-15T11:21:48.878764+00:00","id":476,"links":{},"metadata":{"_buckets":{"deposit":"4b41a289-8311-47b1-9538-9e29471ddb26"},"_deposit":{"created_by":1,"id":"476","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"476"},"status":"published"},"_oai":{"id":"oai:showa.repo.nii.ac.jp:00000476","sets":["1:51:56:58"]},"author_link":["2254","2255","2256","2253","2257","2252","2258","2259"],"item_10002_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018-06"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"315","bibliographicPageStart":"309","bibliographicVolumeNumber":"30","bibliographic_titles":[{"bibliographic_title":"The Showa University journal of medical sciences"}]}]},"item_10002_description_6":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"The safety and efficacy profiles of alectinib versus crizotinib for patients with previously untreated anaplastic lymphoma kinase （ALK）-positive advanced non-small cell lung cancer still remains to be elucidated. We compared the overall efficacies of alectinib and crizotinib for previously untreated ALK-positive advanced non-small cell lung cancer through a meta-analysis of randomized controlled trials. The primary outcome was progression-free survival （PFS）. Pooled estimates were calculated as hazard ratios with 95％ confidence intervals. Two studies on alectinib met the inclusion criteria for this meta-analysis. The hazard ratio （95％ confidence interval） of alectinib for PFS, relative to crizotinib, was 0.41 （0.28-0.60）, demonstrating a superior overall efficacy of alectinib over crizotinib, in terms of PFS.","subitem_description_type":"Abstract"}]},"item_10002_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Showa University Society"}]},"item_10002_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.15369/sujms.30.309"}}]},"item_10002_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0915-6380 "}]},"item_10002_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"MANABE, Ryo"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"ANDO, Koichi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"KUSUMOTO, Sojiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"TANAKA, Akihiko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"YAMAOKA, Toshimitsu"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"OHMORI, Tohru"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"OHNISHI, Tsukasa"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"SAGARA, Hironori"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-07-26"}],"displaytype":"detail","filename":"S30_309.pdf","filesize":[{"value":"427.1 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"S30_309.pdf","url":"https://showa.repo.nii.ac.jp/record/476/files/S30_309.pdf"},"version_id":"6012a8e1-7db1-44a4-8975-b9e2e6319106"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper"}]},"item_title":"Alectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Alectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis"}]},"item_type_id":"10002","owner":"1","path":["58"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-09-05"},"publish_date":"2018-09-05","publish_status":"0","recid":"476","relation_version_is_last":true,"title":["Alectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis"],"weko_creator_id":"1","weko_shared_id":1},"updated":"2023-05-15T12:45:57.632321+00:00"}